Clinical Trial Update: AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating combination therapy of imatinib mesylate and alpha-2a interferon for chronic phase CML patients who are resistant or refractory to imat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib mesylate (Imatinib)
• Interferon alfa-2a (interferon alfa-2a)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: UNKNOWN